Large insider-quality financing at a premium to recent trading with top-tier healthcare investors signals strong institutional conviction. Watch for the Phase 2 CSU data by end of Q3 — positive readout could be a significant catalyst given the company's clinical-stage profile. The registration rights agreement indicates eventual resale, but the locked-in placement structure and lead investor quality reduce near-term overhang risk.
Price Chart
Executive Summary
Cue Biopharma announced a $50M private placement priced at $33.21/share, led by Cormorant Asset Management with participation from Columbia Threadneedle Investments. The capital infusion funds clinical development ahead of a Phase 2 CSU data readout expected by Q3 2026 end.
Key Financial Metrics
Key Facts
- Private placement of 1,418,071 shares at $33.21/share plus pre-funded warrants for 87,500 shares at $33.209
- Gross proceeds of approximately $50.0 million
- Led by Cormorant Asset Management with participation from Columbia Threadneedle Investments
- Priced at $33.21 vs. current market cap of $148M; proceeds represent ~34% of pre-deal market cap
- Expected close on or about July 13, 2026
- Proceeds to fund clinical development and general corporate purposes
- Management guided to Phase 2 CSU data from China by end of Q3 2026
Financial Impact
~$50M gross proceeds representing 34% of pre-offering market cap; dilution of ~1.5M shares (including pre-funded warrants) against existing share base
Risk Factors
- Dilution of ~1.5M shares from the offering and pre-funded warrants
- Pre-funded warrants with $0.001 exercise price create near-term share issuance upon exercise
- Registration rights agreement will eventually enable resale of these shares
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3325290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.40 (+1.47%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.40 (−1.10%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.40 (−17.62%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.40 (−34.93%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.40 (−34.93%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.40 (+23.29%) |
Aug 17, 2026 9w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.40 (+28.42%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.40 (−33.45%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.40 (−46.21%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.40 (−49.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers